Skip to main content

Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction

Buy Article:

$55.00 plus tax (Refund Policy)

Objective: To investigate the expressions of eNOS3 and Ve-cadherin at the first week of reperfused acute myocardial infarction (AMI).

Methods:16 of mini-swines (20 to 30 Kg) were randomly assigned to the sham-operated group and the AMI group. Pathologic myocardial tissue was collected at 7-day of LAD reperfusion and assessed by immunofluorescence and laser co-focus microscope scan, in-situ hybridization, real-time quantitative polymerase chain reaction and western blot.

Results: At 7-day of reperfusion, the eNOS3 mRNA and protein expressions in the infarcted and marginal areas were lower than those in the normal area and sham-operated area (all P<0.05), similarly the infarcted and marginal areas had lower Ve-cadherin mRNA expression than the normal area and the sham-operated area (all P<0.05), and Ve-cadherin protein expression was lower in the infarcted area compared with the marginal area, the normal area and the sham-operated area (all P<0.05).

Conclusion: Lowexpressions of eNOS3 and Ve-cadherin in the salvaged sub-healthy microvascular endothelium of infarcted and marginal areas suggest that endothelial system is impaired at 7-day of reperfused acute myocardial infarction.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Publication date: 2009-06-01

More about this publication?
  • Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more